FIFARMA Regional Observatory
DATA AT THE SERVICE OF EVERYONE
Conozca el Health Innovation Outlook
El Health Innovation Outlook es uno de los estudios más completos que se ha realizado en América Latina, en el que se analizan e integran 55 indicadores, para comparar el desempeño de 11 países de la región en dos dimensiones: salud e innovación. En este estudio se destacan los avances de Argentina, Brasil, Chile, Colombia, Costa Rica, Ecuador, México, Panamá, Perú, República Dominicana y Uruguay y se identifican los retos y oportunidades para fortalecer sus sistemas de salud.
FIFARMA's Regional Observatory is a new data and analysis space for the sector's ecosystem to have the best information for decision making.
FIFARMA makes available to all interested parties this platform that streamlines access to open data from reliable sources, to provide a complete picture of health in the region in one place.
This is a space in constant evolution, at the service of national authorities, companies, unions, academics, and researchers.
EXPLORE THE DASHBOARDS
Health and Innovation Panorama
These data dashboards provide an agile visualization of the main health indicators in three dimensions: country profiles, health indicators and health innovation. This project is a FIFARMA and Innos collaboration for the promotion of transparency and evidence-based decision making.
Country Profile
Health
Innovation
Observatory
of Health Regulatory Policy for Latin America
OPRES monitors and analyzes health policies and regulations in order to disseminate, explain and contribute to their improvement. A deliberation scenario in partnership with Innos.
Latest publications
Understanding the dynamics of the health sector requires analysis, science and in-depth discussions. Learn about the latest reports published by FIFARMA and our strategic allies.
Latam Health Champions Compendium 2024
Innovation plays a critical role in improving public health and in overcoming global health challenges, and robust intellectual property (IP) rights are key in enabling innovation around the world by providing incentives for innovators to invest research and development (R&D) that produce health innovations.
Patient W.A.I.T Indicator 2023 LATAM - Argentina
Though many molecules face reimbursement restrictions and uncertainty surrounding systemic changes exists, Argentina performs better than LATAM regional averages
Patient W.A.I.T Indicator 2023 LATAM - Brazil
Though many molecules face reimbursement restrictions and uncertainty surrounding systemic changes exists, Brazil performs better than LATAM regional averages
Patient W.A.I.T Indicator 2023 LATAM - Chile
Though many molecules face reimbursement restrictions and uncertainty surrounding systemic
changes exists, Colombia performs better than LATAM regional averages
Patient W.A.I.T Indicator 2023 LATAM - Costa Rica
Though many molecules face reimbursement restrictions and uncertainty surrounding systemic changes exists, Costa Rica performs lower than LATAM regional averages
Patient W.A.I.T Indicator 2023 LATAM - Ecuador
Though many molecules face reimbursement restrictions and uncertainty surrounding systemic changes exists, Ecuador performs lower than LATAM regional averages
Patient W.A.I.T Indicator 2023 LATAM - Peru
Though many molecules face reimbursement restrictions and uncertainty surrounding systemic changes exists, Peru performs lower than LATAM regional averages
Patient W.A.I.T Indicator 2023 LATAM - Mexico
Though many molecules face reimbursement restrictions and uncertainty surrounding systemic changes exists, Mexico performs better than LATAM regional averages
Office of Health Economics: según uninforme reciente, los programas devacunación para adultos representanbeneficios socioeconómicos de hasta 19 veces superiores a la inversión inicial
Un nuevo estudio demuestra que los programas de vacunación para adultos
representan un retorno de 19 veces su inversión inicial, si se valora todo el espectro de
beneficios.
Office of Health Economics: programas devacinação para adultos proporcionambenefícios socioeconômicos até 19 vezes doinvestimento inicial, segundo novo relatório
Estudo inovador mostra que os programas de imunização para adultos retornam até 19
vezes o investimento inicial, quando todo o espectro de benefícios é valorizado
Open letter from the biopharmaceutical industry to G20 Ministers in support of the advancement of the G20 Health Agenda
With ongoing negotiations in Geneva and less than six years left to achieve the Sustainable Development Goals (SDGs), the G20 forum serves as a key platform to promote constructive, coordinated, and collaborative solutions.
Carta abierta de la industria biofarmacéutica a los Ministros deSalud del G20 en apoyo al avance de la Agenda de Salud delG20
Con las negociaciones en curso en Ginebra y menos de seis años para lograr los Objetivos de Desarrollo Sostenible (ODS), el foro del G20 sirve como una plataforma clave para promover soluciones constructivas, coordinadas y colaborativas.
Visualizar
Carta aberta da indústria biofarmacêutica aos Ministros do G20 em apoio ao avanço da Agenda de Saúde do G20
Com as negociações em curso em Genebra e menos de seis anos restantes para alcançar os Objetivos de Desenvolvimento Sustentável (ODS), o fórum do G20 atua como uma plataforma fundamental para a promoção de soluções construtivas, coordenadas e colaborativas.
FIFARMA W.A.I.T Indicator 2023 - América Latina
Melhorar a disponibilidade de medicamentos inovadores na América Latina é uma prioridade para todas as partes interessadas no sistema de saúde, especialmente os legisladores, os fabricantes de produtos farmacêuticos e os pacientes.
Explore the databases
Consult the data sources that FIFARMA and its partners make available to researchers, decision makers and authorities in the region.
Contact for researchers
If you have any questions, comments, or requests for information, please contact our team:
Email: info@fifarma.org
